List of Excipients in Branded Drug LIDOCAINE HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
B Braun Medical Inc	LIDOCAINE HYDROCHLORIDE AND DEXTROSE	lidocaine hydrochloride anhydrous and dextrose monohydrate	0264-9598	WATER
Baxter Healthcare Corporation	LIDOCAINE HYDROCHLORIDE AND DEXTROSE	lidocaine hydrochloride	0338-0409	DEXTROSE MONOHYDRATE
Baxter Healthcare Corporation	LIDOCAINE HYDROCHLORIDE AND DEXTROSE	lidocaine hydrochloride	0338-0409	SODIUM HYDROXIDE

Generic Drugs Containing LIDOCAINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	lidocaine hydrochloride	0054-3505	METHYLPARABEN
Hikma Pharmaceuticals USA Inc	lidocaine hydrochloride	0054-3505	SODIUM HYDROXIDE
Xttrium Laboratories Inc	lidocaine hydrochloride	0116-4025	METHYLPARABEN

What are the Most Frequently-Used Excipients in LIDOCAINE HYDROCHLORIDE?

# Of NDCs	Excipient
1	.ALPHA.-TOCOPHEROL, DL-
1	ALCOHOL
5	ANHYDROUS CITRIC ACID

Lidocaine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

Lidocaine hydrochloride is an established, low-cost local anesthetic with broad use in injections, topical liquids, gels, creams, sprays, ophthalmic products, dental preparations, and mucosal treatments. The active ingredient has limited composition-of-matter protection. Commercial value therefore depends on excipient selection, dosage-form performance, preservative strategy, delivery devices, manufacturing efficiency, and regulatory differentiation.

The strongest opportunities are preservative-free multidose alternatives, ready-to-use sterile products, low-irritation topical systems, pediatric and mucosal formulations, and combination products that improve residence time or reduce dosing errors. New chemical entities based only on lidocaine hydrochloride generally face intense generic competition. A differentiated formulation may qualify for a 505(b)(2) pathway when it introduces a clinically meaningful delivery or safety advantage.

What excipients are used with lidocaine hydrochloride?

Lidocaine hydrochloride is water-soluble and is commonly formulated in aqueous systems. Its hydrochloride salt is more suitable for injectable, ophthalmic, nasal, oral-mucosal, and other water-based products than lidocaine base.

Formulation type	Common excipient functions	Typical excipient classes
Injectable solution	Tonicity, pH control, antimicrobial preservation	Sodium chloride, hydrochloric acid, sodium hydroxide, methylparaben, water for injection
Preservative-free injection	pH and tonicity control	Sodium chloride, hydrochloric acid or sodium hydroxide, water for injection
Topical solution	Solubilization, wetting, evaporation control, preservation	Water, ethanol, propylene glycol, polyethylene glycol, preservatives
Viscous oral or mucosal solution	Viscosity, taste masking, retention, preservation	Hydroxyethylcellulose, carboxymethylcellulose, glycerin, sorbitol, flavoring agents, sweeteners
Topical gel	Gel structure, humectancy, spreading, preservation	Carbomers, hydroxyethylcellulose, propylene glycol, glycerin, parabens or phenoxyethanol
Cream or emulsion	Emulsion stability, skin feel, barrier effect	Mineral oil, petrolatum, glycols, fatty alcohols, emulsifiers, preservatives
Ophthalmic formulation	Sterility, comfort, tonicity, pH stability	Sodium chloride, borate or phosphate buffers, purified water, preservatives in multidose formats
Spray	Metered delivery, viscosity control, evaporation	Ethanol, water, polyethylene glycol, propylene glycol, surfactants
Film, patch, or mucoadhesive system	Residence time and controlled release	Povidone, hydroxypropyl methylcellulose, polyvinyl alcohol, polyacrylic acid, plasticizers

The FDA Inactive Ingredient Database provides precedent for excipient use by route, dosage form, and concentration. It should be used to select excipient levels that minimize regulatory novelty while preserving formulation differentiation (FDA, 2024a).

How does lidocaine hydrochloride’s physicochemical profile affect excipient selection?

Lidocaine hydrochloride’s water solubility supports aqueous formulations but creates several formulation constraints.

pH and chemical stability

Lidocaine hydrochloride solutions are generally acidic to mildly acidic. pH adjustment affects solubility, tissue tolerability, preservative performance, and the fraction of un-ionized lidocaine available to cross biological membranes.

A lower pH can improve chemical stability and maintain salt solubility, but injection-site discomfort may increase. Raising pH can improve the proportion of unionized lidocaine and potentially accelerate onset, but excessive alkalinity may produce precipitation or reduce stability.

Commercial formulations should establish:

• pH range during shelf life
• precipitation threshold after dilution
• compatibility with infusion fluids
• stability after vial or syringe opening
• compatibility with elastomeric closures
• degradation products under heat and light stress

Buffers should be used conservatively in injectable products. Strong buffering can limit compatibility with other medicines and complicate terminal sterilization.

Tonicity

Sodium chloride is commonly used to approximate physiologic tonicity in injections and ophthalmic products. Hypotonic or hypertonic systems may cause pain, tissue irritation, or ocular discomfort. Tonicity also affects freeze-thaw stability and the performance of prefilled syringes.

Preservative selection

Multidose injectable products may use antimicrobial preservatives such as methylparaben, while single-dose products generally avoid preservatives. The commercial opportunity is strongest where a manufacturer can provide a preservative-free product without sacrificing container-closure integrity or hospital usability.

Topical and mucosal products may use parabens, phenoxyethanol, benzyl alcohol, sorbic acid, or other preservatives. Selection must account for:

• microbial challenge performance
• route-specific toxicity
• allergy and sensitivity concerns
• interaction with polymers and surfactants
• preservative adsorption to packaging
• regulatory acceptance for neonatal, pediatric, ophthalmic, and mucosal use

A preservative-free claim is commercially meaningful only when supported by validated aseptic processing, container-closure integrity, and in-use stability.

What excipient strategies create the strongest commercial opportunities?

Preservative-free injectable lidocaine hydrochloride

Hospitals use lidocaine hydrochloride injections for local anesthesia, nerve blocks, infiltration, and certain cardiac applications. The core product is commoditized, but suppliers can differentiate through:

• ready-to-use prefilled syringes
• single-dose vials with simplified labeling
• low-waste presentations
• pharmacy bulk packages
• terminally sterilized formats where feasible
• barcode-enabled unit-dose packaging
• reduced-risk closures and low-extractables components

The primary value is operational rather than pharmacological. A ready-to-administer presentation can reduce preparation steps, medication errors, and pharmacy labor.

Low-irritation topical and mucosal products

Topical lidocaine products often contain ethanol, propylene glycol, preservatives, or surfactants that can produce stinging or dryness. Excipient systems that reduce irritation may support premium positioning in dermatology, oral care, anorectal products, and minor procedural anesthesia.

Potential approaches include:

• reducing ethanol concentration
• replacing high-irritation solvents with glycerin or polyethylene glycol
• using hydroxyethylcellulose or carbomer to improve residence time
• incorporating humectants to reduce tissue drying
• using taste-masking systems for oral applications
• lowering preservative burden
• optimizing spray droplet size and deposition

A lower-irritation claim requires comparative clinical or human-tolerance data. It is not established by excipient substitution alone.

Mucoadhesive systems

Lidocaine hydrochloride is rapidly diluted and cleared from oral, nasal, vaginal, rectal, and pharyngeal surfaces. Mucoadhesive polymers can extend contact time and reduce the frequency of application.

Candidate polymers include:

• hydroxypropyl methylcellulose
• hydroxyethylcellulose
• carbomers
• polycarbophil
• chitosan
• polyvinyl alcohol
• povidone

The formulation must balance adhesion with spreadability. Excessive viscosity can impair administration, create an unpleasant mouthfeel, or produce uneven dosing. A mucoadhesive product may support patent claims directed to polymer concentration, release profile, pH, viscosity, dosing device, or treatment method.

Pediatric and taste-masked formulations

Lidocaine hydrochloride’s bitter taste limits oral and mucosal use. Commercial options include:

• sweeteners such as sucrose, sorbitol, or sucralose
• flavor systems
• polymeric taste-masking matrices
• ion-exchange resins
• encapsulated particles
• low-volume concentrated doses
• unit-dose applicators

Taste masking must not compromise dissolution, local anesthetic onset, dose uniformity, or mucosal safety. Pediatric products also require conservative excipient selection. High alcohol content, benzyl alcohol, excessive propylene glycol, and certain surfactants may restrict pediatric use.

Ready-to-use topical delivery devices

Lidocaine hydrochloride can be combined with metered-dose pumps, applicator tips, swabs, films, and premeasured sachets. The device can reduce dosing variability and improve hygiene.

Potential product formats include:

• metered oral sprays
• sterile single-use topical applicators
• prefilled syringes for local infiltration
• anesthetic films
• hydrogel dressings
• disposable dental applicators
• unit-dose rectal or vaginal applicators

Device-related claims can create a stronger commercial position than excipient claims alone, particularly where the device controls dose, deposition site, or exposure time.

What formulations are protected by lidocaine hydrochloride patents?

Lidocaine hydrochloride itself has no meaningful new-molecule patent barrier in ordinary generic markets. Patent value generally resides in the formulation, delivery system, manufacturing process, or therapeutic combination.

Formulation patent categories

Potential claim categories include:

1. A defined lidocaine hydrochloride concentration with a specific pH range.
2. A preservative-free sterile composition with container-closure characteristics.
3. A mucoadhesive composition with specified viscosity or residence time.
4. A low-irritation topical composition with reduced alcohol or glycol content.
5. A sustained-release film, gel, patch, or microsphere.
6. A particular solvent or co-solvent ratio.
7. A stable composition that resists precipitation after dilution.
8. A formulation with a specified impurity profile after sterilization.
9. A combination of lidocaine hydrochloride with another active ingredient.
10. A product packaged in a metered or prefilled delivery device.

Patent durability depends on whether the claims cover a product characteristic that competitors cannot easily avoid. Narrow excipient ranges are often vulnerable to design-around unless they are tied to a demonstrated technical effect.

Manufacturing and packaging IP

Manufacturing barriers may provide more practical protection than composition claims. Relevant subjects include:

• aseptic filling processes
• terminal sterilization cycles
• low-particulate manufacturing
• compatibility with cyclic olefin polymer syringes
• low-extractables elastomeric closures
• oxygen- and light-protective packaging
• high-concentration solution handling
• spray-pump metering accuracy
• film casting and drying processes

A manufacturing patent has greater commercial value when the process materially reduces degradation, particulate formation, or fill-finish cost.

What is the FDA regulatory status of lidocaine hydrochloride products?

Lidocaine hydrochloride is approved in multiple dosage forms and routes, including injection, topical solution, viscous solution, gel, and ophthalmic preparations. Product-specific approval depends on the concentration, route, dosage form, labeling, and excipient system.

Regulatory route	Typical use
Abbreviated New Drug Application	Conventional generic equivalent with the same active ingredient, route, dosage form, strength, and essential performance
505(b)(2) application	New formulation, delivery system, concentration, device, or route relying partly on published or previously approved data
Full NDA	Substantial clinical and nonclinical development for a materially new product
Medical device combination pathway	Lidocaine integrated with a delivery device where the device contributes to product performance

A conventional lidocaine hydrochloride generic usually faces limited clinical development requirements. A novel mucoadhesive, extended-release, pediatric, or device-enabled product may require comparative pharmacokinetic, local tolerability, human-factor, or clinical data.

What is the Orange Book status of lidocaine hydrochloride?

The Orange Book lists approved drug products and applicable patent and exclusivity information for approved applications. For established lidocaine hydrochloride products, commercial entry is generally governed by generic substitution, product-specific application requirements, and formulation or device IP rather than an active composition-of-matter patent.

Orange Book analysis should distinguish:

• the reference listed drug
• approved ANDA products
• any listed patents for the specific reference product
• use codes for method-of-use patents
• pediatric exclusivity
• 30-month stays caused by Paragraph IV litigation
• labeling carve-outs for patented indications

A lidocaine hydrochloride product with a new delivery system may have a different Orange Book profile from an old injectable or topical product. Patent listings must be reviewed at the application level because not every patent covering a formulation is necessarily listed, and not every listed patent blocks all dosage forms.

When does lidocaine hydrochloride lose exclusivity?

Lidocaine hydrochloride has already lost ordinary new-drug exclusivity in its established generic forms. Market exclusivity for a new product would depend on the regulatory pathway and the specific innovation.

Exclusivity type	Commercial relevance
New chemical entity exclusivity	Generally not available for lidocaine hydrochloride
Three-year clinical-investigation exclusivity	May apply to a qualifying new formulation or indication supported by new clinical investigations
Orphan-drug exclusivity	Possible only for a qualifying rare-disease indication
Pediatric exclusivity	Can add six months to existing eligible exclusivity or patent terms
Patent protection	May cover formulation, use, device, process, or packaging
Data exclusivity for a 505(b)(2) product	Depends on the regulatory basis and referenced product

A new formulation must deliver a defensible clinical or technical advantage to sustain premium pricing after generic competition enters.

Are Paragraph IV challenges likely for lidocaine hydrochloride products?

Paragraph IV risk is low for old, unpatented lidocaine hydrochloride products but can become material for a newly approved formulation with listed patents.

Potential challengers include:

• injectable generic manufacturers
• topical dermatology companies
• hospital-focused generic suppliers
• specialty pharmaceutical companies
• contract manufacturers launching private-label products

The most likely Paragraph IV targets would be patents covering a novel gel, film, patch, sustained-release system, device, or combination product. Basic claims to water, sodium chloride, conventional preservatives, or standard viscosity agents are less likely to create durable exclusion.

A settlement agreement could include a licensed generic, an authorized generic, a delayed-entry date, or a covenant not to sue. Settlement economics depend on expected generic conversion, hospital contracting, and the strength of the formulation claims.

Is there biosimilar risk for lidocaine hydrochloride?

Biosimilar risk does not apply. Lidocaine hydrochloride is a small-molecule drug, not a biologic. Competition occurs through ANDAs, 505(b)(2) applications, state substitution rules, hospital tenders, and private-label supply arrangements.

The relevant competitive risks are:

• low-cost injectable generics
• topical OTC products
• compounded preparations
• branded combination products
• alternative local anesthetics such as bupivacaine, mepivacaine, ropivacaine, and prilocaine
• device-based anesthetic systems

How does lidocaine hydrochloride compare with competing local anesthetics?

Product	Main commercial distinction	Excipient and formulation opportunity
Lidocaine hydrochloride	Fast onset, broad use, low cost	Ready-to-use injection, low-irritation topical, mucosal retention
Bupivacaine hydrochloride	Longer duration, slower onset, greater toxicity concerns	Liposomal and extended-release systems
Mepivacaine hydrochloride	Lower vasodilatory effect than lidocaine	Injectable premixes and dental presentations
Ropivacaine hydrochloride	Long duration with regional-anesthesia use	Hospital-focused sterile presentations
Prilocaine	Often combined with lidocaine in topical products	Eutectic creams, patches, and pediatric topical systems

Lidocaine is best positioned where rapid onset, familiarity, price, and route flexibility matter. Longer-acting agents are stronger competitors in postoperative and regional anesthesia, while lidocaine remains attractive for short procedures and topical applications.

Which commercial opportunities have the highest probability of success?

Hospital injectable products

The most realistic opportunity is an operationally superior sterile product, not a new active ingredient. Differentiation can come from:

• preservative-free multidose alternatives
• ready-to-use syringes
• standardized concentrations
• smaller waste volumes
• improved labeling and barcode integration
• reliable supply and fill-finish capacity

Hospital purchasing is price-sensitive, so manufacturing cost and supply continuity are critical.

Dermatology and minor procedures

A topical product can command a premium if it improves onset, comfort, contact time, or application precision. Candidate formats include gels, sprays, films, and low-irritation creams.

Oral and dental care

Taste masking, mucosal adhesion, precise applicators, and unit-dose packaging are commercially relevant. Dental products may benefit from packaging that supports controlled application to a defined site.

Pediatric and caregiver-administered products

Unit-dose formats, child-resistant packaging, low excipient burden, and clear dose measurement can support differentiation. The product must avoid excipients that create age-specific safety concerns.

Compounding and shortage-response markets

Lidocaine hydrochloride products can generate commercial value through reliable sterile manufacturing, especially when hospitals face supply interruptions. This opportunity depends on regulatory compliance, quality systems, and procurement contracts rather than patent exclusivity.

How strong is the patent estate for lidocaine hydrochloride?

The base patent estate is weak because the active ingredient is long established and widely available. A new product can have moderate or strong protection when the claims cover an integrated system that competitors cannot reproduce without losing performance.

Patent strategy	Relative strength
Lidocaine hydrochloride alone	Very weak
Conventional aqueous injection	Weak
Standard topical gel with common polymer	Weak to moderate
Defined low-irritation formulation with clinical support	Moderate
Sustained-release film or patch	Moderate to strong
Device-controlled dose and deposition	Moderate to strong
Manufacturing process reducing impurities or particulates	Moderate
Combination product with a distinct clinical benefit	Moderate to strong

Patent prosecution should focus on measurable performance: onset time, residence time, release rate, reduced irritation, dose uniformity, stability, or reduced systemic exposure. Claims limited to routine excipient substitutions are more exposed to obviousness challenges.

What licensing deals and partnerships are commercially relevant?

Lidocaine hydrochloride is suitable for partnerships involving:

• sterile injectables manufacturing
• prefilled syringe platforms
• topical delivery technologies
• mucoadhesive polymers
• transdermal or buccal films
• pharmaceutical pumps and applicators
• hospital private-label supply
• OTC dermatology and oral-care brands

The preferred deal structure depends on the asset. A conventional generic is more suited to supply, distribution, or contract manufacturing. A differentiated film, patch, or device-enabled product is more suited to an exclusive license with milestone payments and territory-based commercialization rights.

Licensing value should be assessed against:

• formulation patent term
• ANDA or 505(b)(2) timing
• manufacturing scalability
• clinical evidence
• reimbursement and substitution exposure
• hospital purchasing concentration
• expected price erosion after generic entry

What generic launch scenarios exist for lidocaine hydrochloride?

Scenario 1: Conventional generic launch

A manufacturer launches an equivalent injection, topical solution, or gel. Pricing declines rapidly, and market share depends on supply reliability, contract access, and manufacturing cost.

Scenario 2: Authorized or licensed generic competition

A branded formulation owner permits a generic partner to launch under a license. This can preserve volume while reducing the impact of independent ANDA entry.

Scenario 3: 505(b)(2) differentiated launch

A new formulation receives approval based on a previously approved lidocaine product plus new data. The product may obtain limited exclusivity and patent protection but must demonstrate a commercially relevant advantage.

Scenario 4: Device-led premium product

The active formulation remains conventional, while the delivery device controls dose, location, or administration time. The device and combination-product claims provide the principal differentiation.

Key Takeaways

• Lidocaine hydrochloride is a mature small-molecule drug with minimal active-ingredient exclusivity.
• Excipient strategy is most valuable in sterile presentation, irritation reduction, mucosal residence time, taste masking, and dose control.
• Preservative-free injectable products and ready-to-use formats offer the clearest hospital opportunity.
• Mucoadhesive gels, films, and low-irritation topical systems have greater patent and pricing potential than conventional solutions.
• Biosimilar competition does not apply; the relevant threats are ANDA generics, 505(b)(2) products, OTC products, and alternative local anesthetics.
• Stronger patents should claim measurable performance and integrated delivery systems rather than routine excipient substitutions.
• A 505(b)(2) strategy is most credible when the product provides a documented safety, tolerability, dosing, or administration advantage.
• Commercial success will depend more on manufacturing, packaging, contracting, and supply reliability than on the lidocaine hydrochloride molecule itself.

FAQs

Can lidocaine hydrochloride be formulated without preservatives?

Yes. Single-dose injections, ophthalmic products, and certain topical products can be manufactured without preservatives. The product requires appropriate sterile processing, container-closure integrity, and in-use controls.

Which polymers are best for a lidocaine hydrochloride mucoadhesive gel?

Hydroxyethylcellulose, hydroxypropyl methylcellulose, carbomers, polycarbophil, chitosan, and polyvinyl alcohol are potential candidates. The preferred polymer depends on target tissue, viscosity, release rate, tolerability, and manufacturing process.

Can an excipient change support a new lidocaine hydrochloride patent?

Yes, but the claim is stronger when the excipient produces a demonstrated technical effect such as longer mucosal residence, faster onset, lower irritation, improved stability, or controlled release.

Is lidocaine hydrochloride suitable for a 505(b)(2) application?

Yes. A novel route, dosage form, device, concentration, release profile, or clinically differentiated formulation may support a 505(b)(2) application when the regulatory requirements are met.

Which packaging formats offer the greatest differentiation?

Prefilled syringes, metered sprays, sterile single-use applicators, unit-dose sachets, and applicator-controlled topical systems offer the strongest opportunities to reduce dosing variability and improve workflow.

References

1. U.S. Food and Drug Administration. (2024a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024c). Lidocaine hydrochloride injection prescribing information. FDA-approved product labeling.

4. U.S. Food and Drug Administration. (2024d). Guidance for industry: Applications covered by section 505(b)(2). https://www.fda.gov/

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

6. DailyMed. (2024). Lidocaine hydrochloride drug labels. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/